Phase 1 and 2 human trials — what was tested, what was found, why the program stopped, and what it means for researchers today.
Research context only. This page summarizes published clinical data for educational purposes. Not medical advice.
Most research peptides used today never made it past animal studies. AOD-9604 is different — it completed Phase 1 and Phase 2 human trials under a formal clinical development program. Understanding what those trials actually showed (and why they stopped) is essential for anyone researching this compound.
The clinical program was run by Metabolic Pharmaceuticals Ltd in Australia, leveraging Monash University's foundational research. The program spanned nearly a decade of preclinical and clinical work before the company's restructuring halted Phase 3 development.
The key distinction: "No Phase 3 data" is often misread as "the drug failed." For AOD-9604, Phase 3 never happened because the sponsoring company ran out of runway — not because Phase 2 showed problems. The evidence that exists is positive.
Phase 1 trials established that AOD-9604 was safe in healthy human volunteers across a range of doses (50mcg to 1000mcg daily via subcutaneous injection). Key findings:
The Phase 1 data cleared the compound for efficacy testing and established 500mcg/day as the dose to carry forward into Phase 2.
Multiple Phase 2 trials enrolled overweight and obese adults (BMI 25–35) without diabetes. The primary endpoint was change in total body fat mass measured by DEXA scan. Secondary endpoints included visceral fat, lean mass, waist circumference, and metabolic markers.
| Dose (daily SubQ) | Fat Mass Change | IGF-1 Change | Glucose Change |
|---|---|---|---|
| Placebo | Minimal / slight gain | No change | No change |
| 50 mcg | Modest reduction | No change | No change |
| 150 mcg | Moderate reduction | No change | No change |
| 300 mcg | Significant reduction | No change | No change |
| 500 mcg | Significant reduction | No change | No change |
| 1000 mcg | Similar to 500mcg | No change | No change |
The dose-response data suggested a plateau effect above 500mcg — higher doses didn't produce meaningfully greater fat loss. 300–500mcg daily became the research standard as a result.
The selective mechanism confirmed in humans: The most important finding wasn't the fat loss — it was the consistent absence of IGF-1 changes across all dose groups. This validated in human subjects what had been shown in animals: AOD-9604 achieves fat-burning activity through a completely separate pathway from HGH's growth-promoting effects.
Following the clinical trials, AOD-9604 was submitted to the FDA for Generally Recognized As Safe (GRAS) status as a food ingredient. This was granted in 2014 — a meaningful regulatory milestone that reflects the compound's favorable safety profile.
GRAS status as a food ingredient is not the same as drug approval, but it represents formal FDA review of safety data. Very few injectable peptides have any comparable regulatory review on record. This is one reason AOD-9604 occupies a unique position in the research peptide landscape.
What it doesn't mean: GRAS status for food use does not constitute approval for injection or for any therapeutic indication. The gap between "safe as a food ingredient" and "approved drug" is substantial. Don't conflate the two.
AOD-9604's clinical results predate the GLP-1 revolution. When Metabolic Pharmaceuticals was running Phase 2 trials, semaglutide was still in early development. Today the comparison is inevitable:
| Metric | AOD-9604 (Phase 2) | Semaglutide (Phase 3) | Retatrutide (Phase 2) |
|---|---|---|---|
| Mechanism | Direct lipolysis | GLP-1 appetite suppression | GLP-1/GIP/glucagon |
| Avg weight loss | Modest (fat-specific) | ~15% | ~24% |
| IGF-1 effect | None | None | None |
| Blood glucose effect | None | Improves | Improves |
| GI side effects | Minimal | Common | Common |
| Mechanism synergy | Combines with GLP-1 | Standalone | Standalone |
The honest assessment: AOD-9604 produces less total weight loss than modern GLP-1 drugs on its own. But its mechanism is complementary rather than competitive — it directly mobilizes stored fat at the cellular level, something GLP-1 drugs don't specifically do. The combination rationale is real.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator